37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

Development and Optimization of Small Molecule RNA Degraders (IL03)



Prof. Matthew DISNEY
(SCRIPPS RESEARCH INSTITUTE, Jupiter, United States)

Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets (IL05)



Prof. Kyle HADDEN
(UNIVERSITY OF CONNECTICUT, Storrs, United States)

Integrating DNA-Encoded Library Technologies in Lead Discovery (IL01)



Dr Lisa MARCAURELLE
(GSK, Cambridge, United States)

Oral Peptides: Theory and Practice (IL04)



Dr Lauren MONOVICH
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States)

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiD Substrates for Oncology (IL02)



Dr Lewis PENNINGTON
(KYMERA THERAPEUTICS INC., Watertown, United States)

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/cyclin T1 for MYC-dependent Cancers (IL09)



Dr David FREEMAN
(KRONOS BIO, INC. , Massachussetts, United States)

M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies (IL06)



Dr Thomas FUCHSS
(MERCK KGAA, HEALTHCARE, Darmstadt, Germany)

Discovery and Validation of in vitro and in vivo Probes for Human DNA Polymerase Theta (Pol?) (IL07)



Dr Robert HEALD
(ARTIOS PHARMA LTD, Cambridge, United Kingdom)

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Harnessing CDK12 Inhibition of Transcriptional Machinery to Induce Dimerization between DDB1 and CDK12-cyclinK Complex for Targeted Protein Degradation (IL10)



Prof. Andrii MONASTYRSKYI
(MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, United States)

The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response (IL08)



Prof. Phil REIGAN
(UNIVERSITY OF COLORADO, Aurora, United States)

Session 3: Hot Targets from NYC Academic and Biotech Scene

Designing and Combining Cancer's Off Switches (IL15)



Dr Karen AKINSANYA
(SCHRODINGER, New York City, United States)

Rational Design of Inhibitors of Protein-Protein Interactions (IL11)



Prof. Paramjit ARORA
(NYU, New York, United States)

Next Generation Drug Discovery (IL12)



Dr Steve COLLETTI
(ZYMERGEN INC., New York, United States)

Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd) (IL13)



Dr John GINN
(TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States)

Therapeutic Potential of the Gut-Brain Axis (IL14)



Dr Iyassu SEBHAT
(KALLYOPE, New Jersey, United States)

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

Chasing Challenging Targets: Development of Selective Inhibitors of the Autophagy Pathway to Impact Cancer Therapy (IL19)



Prof. Leslie ALDRICH
(UNIVERISTY OF ILLINOIS AT CHICAGO, Chicago, United States)

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Revolutionizing Discovery and Development of ALS Therapeutics using Transformational, AI-powered 'All-in-Human' Platforms (IL18)



Dr Irene CHOI
(VERGE GENOMICS, South San Francisco, United States)

Necessary Complexity: The Discovery of Selective, CNS Penetrant LRRK2 Inhibitors for the Treatment of Parkinson's Disease (IL21)



Dr Peter FULLER
(MERCK & CO. INC., Boston, United States)

Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration (IL20)



Prof. Evripidis GAVATHIOTIS
(ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States)

Small Molecule PINK1 Activators Rescue Parkinson's Disease Pathology (IL17)



Dr Nicholas HERTZ
(MITOKININ INC, San Francisco, United States)

Unraveling Autophagy in Cancer Using Chemical Genetics (IL16)



Prof. Jeff MACKEIGAN
(MICHIGAN STATE UNIVERSITY, East Lansing, United States)

Session 5: Next Generation Therapies Shaped by Clinical Data

Discovery of Inavolisib, a Highly Selective Inhibitor of PI3K-? that Induces Degradation of Mutant-p110? Protein (IL25)



Dr Marie-Gabrielle BRAUN
(GENENTECH, South San Francisco, United States)

Discovery of LPA1 antagonists for the treatment of Pulmonary Fibrotic Diseases (IL22)



Dr Peter CHENG
(BRISTOL-MYERS SQUIBB R & D, Hopewell, United States)

Discovery of Risdiplam, a Medicine for the Treatment of Spinal Muscular Atrophy (IL23)



Dr Luke GREEN
(HOFFMANN-LA ROCHE, Basel, Switzerland)

Discovery of PF-07081532: a Small Molecule GLP-1 Receptor Agonist Suitable for Once-daily Oral Administration (IL26)

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers



Dr David A. GRIFFITH
(PFIZER INC., Cambridge, United States)

Discovery of LY3154885, a Second Generation Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (IL27)



Dr Erik HEMBRE
(ELI LILLY & CO., Indianapolis, United States)

The Invention of MK-8262, a CETP Inhibitor for the Treatment of Coronary Heart Disease (IL24)



Dr Petr VACHAL
(MERCK & CO. INC (MSD), Kenilworth, United States)

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

Discovery of Nix-TB as a Novel Regimen that Significantly Shortens Treatment of Tuberculosis (IL31)



Dr Christopher B. COOPER
(TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States)

Small Molecule Drug Discovery in Academia: DYRK1A Inhibitors as Novel beta-Cell Regenerative Drugs for Diabetes (IL28)



Prof. Robert DEVITA
(ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, NY, United States)

Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor (IL29)



Dr Kristine E. FRANK
(ABBVIE, North Chicago, United States)

Anticancer Drug Discovery from Pets to People, the Story of PAC-1 (IL30)



Prof. Paul J. HERGENROTHER
(UNIVERSITY OF ILLINOIS, Urbana, United States)

Adventures in Drug Hunting (IL32)



Dr Wendy YOUNG
(MPM CAPITAL, Brisbane, CA, United States)

Award Session

2022 Division of Medicinal Chemistry Award Lecture
A Perspective on the Arc of Innovation in Drug Discovery over Three Decades (AL01)

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers



Dr Lawrence G. HAMANN
(INTERDICT BIO, San Francisco, United States)

2022 IUPAC-Richter Prize Lecture
Drug Discovery in Academia: Some Success Stories (AL02)



Prof. Michael E. JUNG
(UCLA CHEMISTRY & BIOCHEMISTRY, Los Angeles, United States)